Meiji Seika Is Latest To Kick Off Ustekinumab Phase III

Sees Positive Phase I Results For Stelara Biosimilar With Dong-A Socio Holdings

 
• By Dave Wallace

Meiji Seika and Dong-A Socio Holdings have become the latest developers to announce the start of Phase III trials for an ustekinumab biosimilar rival to Stelara.  

Starting blocks sprint race
Several companies are jostling for position on biosimilar Stelara • Source: Alamy

More from Biosimilars

More from Products